Q2 2025 Doximity Inc Earnings Call Transcript
Key Points
- Doximity Inc (DOCS) reported $137 million in revenue for Q2 fiscal 2025, marking a 20% year-on-year growth and exceeding the high end of their guidance range by 7%.
- The company achieved a record adjusted EBITDA margin of 56%, representing a 41% year-on-year growth and 20% above the high end of their guidance.
- Doximity Inc (DOCS) saw record engagement levels, with unique active users increasing double-digit percentages across quarterly, monthly, weekly, and daily metrics.
- The company's workflow tools, including telehealth and AI assistance, set new records with over 600,000 unique active prescribers, and AI tools grew the fastest with over 1 million Doximity GPT prompts in Q2.
- The new client portal has been well-received, with over 40% of pharma brand clients using it, leading to strong sales growth and easier upsells, particularly with nurse practitioner audience extensions.
- Despite strong performance, Doximity Inc (DOCS) anticipates potential longer launch timelines for new workflow products, which could impact Q4 revenue.
- The company is experiencing evolving industry dynamics, leading to quarterly variations in revenue growth and changes in the shape of the fiscal year.
- There is uncertainty regarding the long-term growth rate of the pharma digital market, which affects the company's ability to provide updated long-term financial targets.
- Doximity Inc (DOCS) is still in the early stages of understanding how AI and the client portal could impact incremental margins, making it difficult to predict medium to long-term margin outcomes.
- The company faces challenges in maintaining pricing power, as pricing is not the primary growth lever and the market environment remains competitive.
Well, good day, everyone, and welcome to the Doximity fiscal 2Q '25 earnings call. At this time, I would like to hand the call over to Mr. Perry Gold. Please go ahead, sir.
Thank you, operator. Hello, and welcome to Doximity fiscal 2025 second-quarter earnings call.
With me on the call today are Jeff Tangney, Co-Founder and CEO of Doximity; Dr. Nate Gross, Co-Founder and CSO; and Anna Bryson, CFO. A complete disclosure of our results can be found in our press release issued earlier today, as well as in our related Form 8-K, along with a copy of our prepared remarks all available on our website at investors.doximity.com. As a reminder, today's call is being recorded, and a replay will be available on our website.
As part of our comments today, we will be making forward-looking statements. These statements are based on management's current views, expectations and assumptions, and are subject to various risks and uncertainties. Actual results may differ materially, and we disclaim any
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
